<DOC>
	<DOC>NCT00605137</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of trial is to investigate the safety of insulin detemir and insulin NPH in children with type 1 diabetes.</brief_summary>
	<brief_title>Safety of Insulin Detemir in Children With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetes for at least one year Current treatment of basalbolus regimen for at least 12 weeks using an intermediate/longacting human insulin and insulin aspart and/or soluble human insulin HbA1C below 11.0% Willing to comply with Investigator's instructions Able and willing to perform selfmonitoring of capillary blood glucose and to take measures in case of hypoglycaemia Impaired renal function Impaired hepatic function Known hypoglycaemia unawareness or recurrent major hypoglycaemia (as judged by the Investigator or SubInvestigator) Proliferative retinopathy or maculopathy requiring acute treatment Uncontrolled treated/untreated hypertension Current treatment with total daily insulin dose of more than 2.00 IU/kg Current treatment or expected at the screening to start treatment with systemic corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>